Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders : systematic review and meta-regression analysis
| dc.contributor.author | Suliman, Sharain | |
| dc.contributor.author | Hemmings, Sian M. J. | |
| dc.contributor.author | Seedat, Soraya | |
| dc.date.accessioned | 2013-08-07T06:04:12Z | |
| dc.date.available | 2013-08-07T06:04:12Z | |
| dc.date.issued | 2013-07 | |
| dc.description | Publication of this article was funded by the Stellenbosch University Open Access Fund. | en_ZA |
| dc.description | The original publication is available at http://www.frontiersin.org/Integrative_Neuroscience | en_ZA |
| dc.description.abstract | Background: Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that is involved in the synaptic plasticity and survival of neurons. BDNF is believed to be involved in the pathogenesis of several neuropsychiatric disorders. As findings of BDNF levels in anxiety disorders have been inconsistent, we undertook to conduct a systematic review and meta-analysis of studies that assessed BDNF protein levels in these disorders. Methods: We conducted the review using electronic databases and searched reference lists of relevant articles for any further studies. Studies that measured BDNF protein levels in any anxiety disorder and compared these to a control group were included. Effect sizes of the differences in BDNF levels between anxiety disorder and control groups were calculated. Results: Eight studies with a total of 1179 participants were included. Initial findings suggested that BDNF levels were lower in individuals with any anxiety disorder compared to those without [Standard Mean Difference (SMD) = −0.94 (−1.75, −0.12), p≤0.05]. This was, however, dependent on source of BDNF protein [plasma: SMD =−1.31 (−1.69, −0.92), p≤0.01; serum: SMD = −1.06 (−2.27, 0.16), p≥0.01] and type of anxiety disorder [PTSD: SMD = −0.05 (−1.66, 1.75), p≥0.01; OCD: SMD = −2.33 (−4.21, −0.45), p≤0.01]. Conclusion: Although BDNF levels appear to be reduced in individuals with an anxiety disorder, this is not consistent across the various anxiety disorders and may largely be explained by the significantly lowered BDNF levels found in OCD. Results further appear to be mediated by differences in sampling methods. Findings are, however, limited by the lack of research in this area, and given the potential for BDNF as a biomarker of anxiety disorders, it would be useful to clarify the relationship further. | en_ZA |
| dc.description.sponsorship | Stellenbosch University | en_ZA |
| dc.description.version | Publishers' version | en_ZA |
| dc.format.extent | 11 p. | |
| dc.identifier.citation | Suliman, S., Hemmings, S.M.J. & Seedat, S. 2013. Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Frontiers in Integrative Neuroscience, 7(55):1-11, doi:10.3389/fnint.2013.00055. | en_ZA |
| dc.identifier.issn | 1662-5145 (online) | |
| dc.identifier.other | doi:10.3389/fnint.2013.00055 | |
| dc.identifier.uri | http://hdl.handle.net/10019.1/85306 | |
| dc.language.iso | en_ZA | en_ZA |
| dc.publisher | Frontiers | en_ZA |
| dc.rights.holder | Authors retain copyright | en_ZA |
| dc.subject | Neurotrophic functions | en_ZA |
| dc.subject | Anxiety disorders | en_ZA |
| dc.title | Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders : systematic review and meta-regression analysis | en_ZA |
| dc.type | Article | en_ZA |